Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 4, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,975,000 ordinary shares of 25 pence each.
- Purchase Price: 1,134.66 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 8.94% of total voting rights).
- Shares in Issue: 5,413,328,610 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,975,000 shares purchased on April 4, 2008. Consequently, the number of shares held in Treasury has increased to 484,194,158. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the share repurchase by multiplying 1,975,000 shares by 1,134.66 pence.
- Confirm the updated total voting rights denominator (5,413,328,610 shares) for compliance with disclosure thresholds.
- Note that 8.94% of the company's voting rights are currently held in Treasury.
- Recognize that this filing is a transactional report and does not contain quarterly or annual financial performance data.